129 related articles for article (PubMed ID: 10807974)
21. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.
Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):679-83. PubMed ID: 11214775
[TBL] [Abstract][Full Text] [Related]
22. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians.
McLellan RA; Oscarson M; Seidegård J; Evans DA; Ingelman-Sundberg M
Pharmacogenetics; 1997 Jun; 7(3):187-91. PubMed ID: 9241658
[TBL] [Abstract][Full Text] [Related]
23. [Allele specific amplification for CYP2D6 gene related to intermediate metabolizer in Chinese subjects].
Chen B; Cai WM; Ling SS
Yao Xue Xue Bao; 2001 Feb; 36(2):88-91. PubMed ID: 12579870
[TBL] [Abstract][Full Text] [Related]
24. A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
Johansson H; Gandini S; Serrano D; Gjerde J; Lattanzi M; Macis D; Guerrieri-Gonzaga A; Aristarco V; Mellgren G; Lien E; DeCensi A; Bonanni B
Breast Cancer Res Treat; 2016 Aug; 159(1):97-108. PubMed ID: 27484880
[TBL] [Abstract][Full Text] [Related]
25. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
26. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
27. Alternative reliable method for cytochrome P450 2D6 poor metabolizers genotyping.
Pindurová E; Zourková A; Zrůstová J; Juřica J; Pavelka A
Mol Biotechnol; 2013 Jan; 53(1):29-40. PubMed ID: 22367691
[TBL] [Abstract][Full Text] [Related]
28. Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response.
Yadav SS; Ruwali M; Pant MC; Shukla P; Singh RL; Parmar D
Mutat Res; 2010 Feb; 684(1-2):49-55. PubMed ID: 19954746
[TBL] [Abstract][Full Text] [Related]
29. Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease.
Tsuneoka Y; Matsuo Y; Ichikawa Y; Watanabe Y
Metabolism; 1998 Jan; 47(1):94-6. PubMed ID: 9440484
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome P450 2D6 polymorphism and drug utilization in patients with oral lichen planus.
Paulusová V; Rösch C; Drízhal I; Perlík F; Masín V; Sukumar S; Slezák R; Slanar O
Acta Odontol Scand; 2010 Jul; 68(4):193-8. PubMed ID: 20201714
[TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphisms of CYP2D6 oxidation in patients with inflammatory bowel disease.
Trzcinski R; Skretkowicz J; Dziki A; Rychlik-Sych M; Baranska M
Dig Dis Sci; 2010 Apr; 55(4):1037-43. PubMed ID: 19437119
[TBL] [Abstract][Full Text] [Related]
32. Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.
Karle J; Bolbrinker J; Vogl S; Kreutz R; Denkert C; Eucker J; Wischnewsky M; Possinger K; Regierer AC
Breast Cancer Res Treat; 2013 Jun; 139(2):553-60. PubMed ID: 23686417
[TBL] [Abstract][Full Text] [Related]
33. CYP2D6*4 allele and breast cancer risk: is there any association?
Fernández-Santander A; del Saz Sánchez M; Tejerina Gómez A; Bandrés Moya F
Clin Transl Oncol; 2012 Feb; 14(2):157-9. PubMed ID: 22301406
[TBL] [Abstract][Full Text] [Related]
34. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
35. No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population.
Scordo MG; Dahl ML; Spina E; Cordici F; Arena MG
Pharmacol Res; 2006 Feb; 53(2):162-5. PubMed ID: 16337409
[TBL] [Abstract][Full Text] [Related]
36. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR.
Hersberger M; Marti-Jaun J; Rentsch K; Hänseler E
Clin Chem; 2000 Aug; 46(8 Pt 1):1072-7. PubMed ID: 10926885
[TBL] [Abstract][Full Text] [Related]
37. Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes.
Senda C; Yamaura Y; Kobayashi K; Fujii H; Minami H; Sasaki Y; Igarashi T; Chiba K
Br J Clin Pharmacol; 2001 Jul; 52(1):100-3. PubMed ID: 11453897
[TBL] [Abstract][Full Text] [Related]
38. Incidence of inactive allele CYP2D6*4 among Greek women suffering from hormone-sensitive breast cancer.
Kykalos S; Mantas D; Charalampoudis P; Kouraklis G; Markopoulos C
Eur J Gynaecol Oncol; 2016 Aug; 37(4):504-510. PubMed ID: 29894075
[TBL] [Abstract][Full Text] [Related]
39. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
Arneth B; Shams M; Hiemke C; Härtter S
Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
[TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphism of CYP2D6 in the Japanese population.
Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
